Mutations in ATRX are predominantly loss of function and are enriched in specific cancer types, including low-grade gliomas, soft tissue sarcomas, pancreatic neuroendocrine tumors, and uterine corpus endometrial carcinomas (2–5). This evidence concerns the gene ATRX and soft tissue sarcoma.